Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.1
4.7
Journals
Viruses
Special Issues
Nanomedicine Applied in the Control and Diagnosis of Viral Infections
share announcement

Nanomedicine Applied in the Control and Diagnosis of Viral Infections

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 6156

Special Issue Editors

Prof. Dr. Flavio Guimaraes da Fonseca

E-Mail Website
Guest Editor
Vaccine Development Center, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte 31270-901, Brazil
Interests: viral vaccines; viral diagnostics; nanomaterials applied to viral biotechnologies
Special Issues, Collections and Topics in MDPI journals
Dr. Luiz Felipe Leomil Coelho

E-Mail Website
Guest Editor
Vaccine Laboratory, Biomedical Institute, Federal University of Alfenas, Alfenas 37130-001, Brazil
Interests: vaccines; nanoparticles; arbovirus; diagnostic tests; adjuvant nanoparticles
Dr. Breno de Mello Silva

E-Mail Website
Guest Editor
Biology and Technology of Microorganisms Laboratory, Institute of Exact and Biological Sciences, Federal University of Ouro Preto, Ouro Preto 35400-000, Brazil
Interests: arbovirus; viral diagnostics; nanomaterials applied to viral biotechnologies

Special Issue Information

Dear Colleagues, 

Nanomedicine is a new and emerging subject of research that aims to develop innovative technologies to diagnose, treat or prevent diseases. Nanomedicine brings together pharmaceutical and biomedical sciences to produce nanoparticles able to deliver drugs and antigens, perform diagnosis, and also improve safety and toxicity. Nanoparticles can be used to develop new vaccines, diagnostic tests, and treatments for infectious diseases, and therefore, this approach could be a new alternative to solve important problems in diseases caused by viruses. Nanoparticles can have an intrinsic antiviral activity or improve the antiviral activity of some compounds, can be used as part of biosensors to detect the whole virus, viral antigens, or viral genome and also improve immune response triggered by vaccination. Recent advances in this area of research have shown the potential application of nanoparticle systems in the control and diagnosis of viral infections. Therefore, this Special Issue is focused on recent advances, methods, and approaches in preparing nanoparticles to treat (antiviral action), detect (diagnostic tests), and prevent (vaccines) viral diseases.

Prof. Dr. Flavio Guimaraes da Fonseca
Dr. Luiz Felipe Leomil Coelho
Dr. Breno de Mello Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Prof. Dr. Flavio Guimaraes da Fonseca
Dr. Luiz Felipe Leomil Coelho
Dr. Breno de Mello Silva
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomedicine for antiviral therapy
  • nanomedicine for diagnostic of viral infections
  • nanomedicine strategies for viral vaccine delivery
  • nanoparticle-based biosensors for viral diagnosis
  • virus-like particles and nanotechnology
  • nanotechnology and viruses

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

25 pages, 4163 KiB  
Article
Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies
by Kanasap Kaewchim, Kittirat Glab-ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung and Wanpen Chaicumpa
Viruses 2023, 15(6), 1252; https://doi.org/10.3390/v15061252 - 26 May 2023
Cited by 4 | Viewed by 1441 | Correction
Abstract
Engineered nanobodies (VHs) to the SARS-CoV-2 receptor-binding domain (RBD) were generated using phage display technology. A recombinant Wuhan RBD served as bait in phage panning to fish out nanobody-displaying phages from a VH/VHH phage display library. Sixteen phage-infected E. coli clones [...] Read more.
Engineered nanobodies (VHs) to the SARS-CoV-2 receptor-binding domain (RBD) were generated using phage display technology. A recombinant Wuhan RBD served as bait in phage panning to fish out nanobody-displaying phages from a VH/VHH phage display library. Sixteen phage-infected E. coli clones produced nanobodies with 81.79–98.96% framework similarity to human antibodies; thus, they may be regarded as human nanobodies. Nanobodies of E. coli clones 114 and 278 neutralized SARS-CoV-2 infectivity in a dose-dependent manner; nanobodies of clones 103 and 105 enhanced the virus’s infectivity by increasing the cytopathic effect (CPE) in an infected Vero E6 monolayer. These four nanobodies also bound to recombinant Delta and Omicron RBDs and native SARS-CoV-2 spike proteins. The neutralizing VH114 epitope contains the previously reported VYAWN motif (Wuhan RBD residues 350–354). The linear epitope of neutralizing VH278 at Wuhan RBD 319RVQPTESIVRFPNITN334 is novel. In this study, for the first time, we report SARS-CoV-2 RBD-enhancing epitopes, i.e., a linear VH103 epitope at RBD residues 359NCVADVSVLYNSAPFFTFKCYG380, and the VH105 epitope, most likely conformational and formed by residues in three RBD regions that are spatially juxtaposed upon the protein folding. Data obtained in this way are useful for the rational design of subunit SARS-CoV-2 vaccines that should be devoid of enhancing epitopes. VH114 and VH278 should be tested further for clinical use against COVID-19. Full article
(This article belongs to the Special Issue Nanomedicine Applied in the Control and Diagnosis of Viral Infections)
►▼ Show Figures

Figure 1

Review

Jump to: Research, Other

34 pages, 2271 KiB  
Review
Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies
by Londiwe Simphiwe Mbatha, Jude Akinyelu, Chika Ifeanyi Chukwuma, Mduduzi Paul Mokoena and Tukayi Kudanga
Viruses 2023, 15(3), 741; https://doi.org/10.3390/v15030741 - 13 Mar 2023
Cited by 9 | Viewed by 3600
Abstract
Cancer and COVID-19 have been deemed as world health concerns due to the millions of lives that they have claimed over the years. Extensive efforts have been made to develop sophisticated, site-specific, and safe strategies that can effectively diagnose, prevent, manage, and treat [...] Read more.
Cancer and COVID-19 have been deemed as world health concerns due to the millions of lives that they have claimed over the years. Extensive efforts have been made to develop sophisticated, site-specific, and safe strategies that can effectively diagnose, prevent, manage, and treat these diseases. These strategies involve the implementation of metal nanoparticles and metal oxides such as gold, silver, iron oxide, titanium oxide, zinc oxide, and copper oxide, formulated through nanotechnology as alternative anticancer or antiviral therapeutics or drug delivery systems. This review provides a perspective on metal nanoparticles and their potential application in cancer and COVID-19 treatments. The data of published studies were critically analysed to expose the potential therapeutic relevance of green synthesized metal nanoparticles in cancer and COVID-19. Although various research reports highlight the great potential of metal and metal oxide nanoparticles as alternative nanotherapeutics, issues of nanotoxicity, complex methods of preparation, biodegradability, and clearance are lingering challenges for the successful clinical application of the NPs. Thus, future innovations include fabricating metal nanoparticles with eco-friendly materials, tailor making them with optimal therapeutics for specific disease targeting, and in vitro and in vivo evaluation of safety, therapeutic efficiency, pharmacokinetics, and biodistribution. Full article
(This article belongs to the Special Issue Nanomedicine Applied in the Control and Diagnosis of Viral Infections)
►▼ Show Figures

Graphical abstract

Other

Jump to: Research, Review

2 pages, 392 KiB  
Correction
Correction: Kaewchim et al. Neutralizing and Enhancing Epitopes of the SARS-CoV-2 Receptor-Binding Domain (RBD) Identified by Nanobodies. Viruses 2023, 15, 1252
by Kanasap Kaewchim, Kittirat Glab-ampai, Kodchakorn Mahasongkram, Thanatsaran Saenlom, Watayagorn Thepsawat, Monrat Chulanetra, Kiattawee Choowongkomon, Nitat Sookrung and Wanpen Chaicumpa
Viruses 2023, 15(10), 1979; https://doi.org/10.3390/v15101979 - 22 Sep 2023
Viewed by 521
Abstract
In the original publication [...] Full article
(This article belongs to the Special Issue Nanomedicine Applied in the Control and Diagnosis of Viral Infections)
►▼ Show Figures

Figure 6

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop